Clinical Trial Update: Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II trial evaluating Selinexor (KPT-330) in combination with Sorafenib for acute myeloid leukemia has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Selinexor (selinexor)
• Sorafenib (Sorafenib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia, Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-03-31